Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ―

Read more at globenewswire.com